Company / Operating Cash Flow
Protagonist Therapeutics, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$57.7M
FY2025
5-year range
-$108.1M / $184.2M
FY2021-FY2025
Trend
-68.7%
vs FY2024
Sector context
#57 of 216
Health Care
What the data says
At $58M, Protagonist Therapeutics, Inc.'s operating cash flow ranks #57 of 216 in the Health Care sector. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$108M in FY2022 to $184M in FY2024.
Based on SEC 10-K filings.
$58M in FY2025.
Improved from -$70M to $58M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#57 of 216 in Health CareTop 26% of 216This company $57.7M Sector average $658.7M
▼
-91.2% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 68.7% year-over-year.
- Ranks #57 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2024.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 4.66 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $57.7M | -68.7% |
| FY2024 | $184.2M | +362.2% |
| FY2023 | -$70.2M | +35.0% |
| FY2022 | -$108.1M | -0.3% |
| FY2021 | -$107.9M | -48.8% |
| FY2020 | -$72.5M | -74.5% |
| FY2019 | -$41.5M | +16.9% |
| FY2018 | -$49.9M | -1390.0% |
| FY2017 | $3.9M | +112.9% |
| FY2016 | -$30.0M | -108.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026